Navigation Links
OncoSec Announces Leadership Team Appointments
Date:5/11/2011

SAN DIEGO, May 11, 2011 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers that have unmet medical needs, announced today the appointment of three members to its leadership team. Formed earlier this year, OncoSec expects to initiate Phase II clinical trials for its tumor-destroying, tissue-sparing ElectroOncology therapies before the end of this year.

(Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

OncoSec's novel targeted tumor therapies are designed to address the drawbacks of conventional therapies by being tissue sparing; providing potential functional, cosmetic and quality of life benefits; being less invasive and reducing side effects; and potentially reducing both treatment and post-treatment costs. Based on extensive past validating data from human studies, OncoSec expects to initiate advanced stage clinical studies for its ElectroImmunotherapy and ElectroChemotherapy programs.

It is estimated that half of the 1.4 million cancers diagnosed each year in the United States are solid-tumor cancers.  Cancers of the lung, prostate, colon, rectum or breast cancer are all solid tumor cancers. The National Institutes of Health estimated the annual cost of cancer to be $228.1 billion in 2008.

Today, Punit Dhillon, OncoSec's co-founder, President and CEO, announced the following management appointments:

Dr. Michael Cross, Chief Business Officer

Michael Cross, PhD, a co-founder of OncoSec, will serve as Chief Business Officer. He will be responsible for business development, engineering operations, partnerships and fundraising, among other duties. Dr. Cross, who holds an MBA, has nearly two decades of life sciences venture capital and biotech industry experience. Prior to joining OncoSec, Dr. Cross was Vice President at Growt
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoSec Medical Featured in Medical Device Daily
2. OncoSec Medical Appoints Punit Dhillon as President and CEO
3. Brainlab Announces FDA 510(k) Clearance for New HybridArc™ Software for Radiosurgery
4. Mtech Announces Winners of the 2011 University of Maryland $75K Business Plan Competition
5. PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015
6. Advanced Cell Technology Announces 2011 First Quarter Results
7. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
8. Cell Biosciences Announces Issuance of Three US Patents
9. Cord Blood America Announces BioCells, Inc., Which it Acquired in 2010, is Opening Office in Miami, Florida and 5 New Offices in Argentina Soon
10. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
11. Cord Blood America Announces Reverse Stock Split Takes Effect Monday, May 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... Systems Inc.,(Amex: PLC ) today announced that it ... dated September 17, 2008 from the Listing,Qualifications Department staff ... Company was not in compliance with Section 1003(a)(ii) of,the ... less,than $4,000,000 as of June 30, 2008, and it ...
... 18 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a ... anti-adhesion, drug delivery products and other,surgical implants, announced ... the,AdvaMed 2008 MedTech conference being held in Washington, ... and CEO of SyntheMed, is scheduled,to present on ...
... NOVATO, Calif., Sept. 18 BioMarin,Pharmaceutical Inc. (Nasdaq: ... article released by Bloomberg this morning. The article ... Chief Executive Officer of,BioMarin, held on September 17, ... is consistent with the,information previously released publicly:, ...
Cached Biology Technology:PLC Systems Receives Delisting Notice From American Stock Exchange 2SyntheMed To Present at the AdvaMed 2008 MedTech Conference 2BioMarin Corrects Information Included in Bloomberg Article 2BioMarin Corrects Information Included in Bloomberg Article 3
(Date:4/23/2014)... A biomedical engineer at the University of Houston ... make blood transfusions safer. His work is supported by ... Health (NIH). , Blood transfusions save millions of ... absolute necessities. Without them, for instance, routine surgeries would ... however. There,s strong evidence that transfusions of red blood ...
(Date:4/22/2014)... secret to get your child to behave at the dinner ... Cornell study published in Eating Behaviors , found that ... bite with their front teeth such as drumsticks, whole apples, ... when these foods had been cut. "They were twice ... other kids," said Brian Wansink, Professor and Director of the ...
(Date:4/22/2014)... Biotechnology scientists must be aware of the broad ... guidelines, according to a new paper from Rice University,s ... current issue of the journal Regenerative Medicine , ... Supreme Court ruling in the case Association for Molecular ... are unpatentable. The court case and rulings garnered discussion ...
Breaking Biology News(10 mins):UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Biting vs. chewing 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... http://www.biologists.com/ ) organises and supports a themed conference as the ... of Experimental Biology . The main aim of this annual ... varied expertise on one particular subject. It is a leisurely ... social side of science is also catered for an ...
... survive chemotherapy leaving the door open to recurrence ... an original method for imaging and analyzing many thousands ... drug affects each one. For research student ... in the lab of Prof. Uri Alon of the ...
... The University of Nottingham have been involved in a scientific ... be more likely to suffer from the chronic skin condition, ... the journal Nature Genetics , shows that people who ... be affected by psoriasis. These two genes appear to be ...
Cached Biology News:Survival in a Changing World: The Journal of Experimental Biology 2009 symposium 2Weizmann Institute scientists discover how cancer cells survive a chemotherapy drug 2Missing genes link to psoriasis 2
... Disrupts biological cells for DNA isolation. ... well plates (includes 96 well plate ... lysis across the entire plate length ... Can be used for soil, ...
Request Info...
GBL Antibody...
Dnase and Rnase free...
Biology Products: